Relative Bioavailability and Pharmacokinetics of Evobrutinib

Phase 1, randomised, open-label trial of evobrutinib in multiple sclerosis (MS) (5 arms), sponsored by Merck KGaA. Primary endpoints: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to 24 Hours Post Dose [Frel(AUC0-24)] and Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Infinity [Frel(AUC0-inf)]. Started Feb 2022; status: completed.